Phase II Study of Combination Epitope Peptides with gemcitabine for Advanced/metastatic Pancreatic Cancer

Phase II Study of Combination Epitope Peptides with gemcitabine for Advanced/metastatic Pancreatic Cancer - Phase II Study of Combination Epitope Peptides with gemcitabine for Advanced/metastatic Pancreatic Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005301

Enrollment

Registered

2011-04-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced/metastatic Pancreatic Cancer

Interventions

Combination Epitope Peptides with gemcitabine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histological proven pancreatic cancer 2. age: over 20 years-old, under 80 years-old 3.PS:0 to 1(ECOG performance status score) 4. One or more RECIST lesions 5.chemo-naive 6. Good function of critical organs 7. Suspect for more than 3 months alive 8. Written informed consents 9.not to have rapid growth of liver metastasis and much ascites

Exclusion criteria

Exclusion criteria: 1. Severe heart diseases 2. Wish for pregnancy 3. Active infection 4. Steroid or immunosuppressive therapy 5. Allergy for using epitope peptides 6. Mental and nervous disorder 7. Massive pleural or abdominal effusions 8. Rapid growth of liver metastasis 9. Doctors opinion

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Response rate Progression free survival Safety Disease control rate specific immune response	—

Countries

Japan

Contacts

Public ContactNobuaki Suzuki

YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE Department of Digestive Surgery and Surgical Oncology

nobusuzu@yamaguchi-u.ac.jp0836-22-2264

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026